certificate of analysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-30. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
== Polyphenols == Citrus fruits contain polyphenols, which may include furanocoumarins and naringin, such as bergamottin, dihydroxybergamottin, and bergapten. Grapefruit, Seville oranges, and bergamot contain naringin. Furanocoumarins may have a stronger effect than naringin.
(chaotropic) When oppositely charged kosmotropic cations and anions are in solution together, they are attracted to each other, rather than to water, and the same can be said for chaotropic cations and anions. Thus, the preferential associations of oppositely charged ions can be ordered as:
=== Consumer product development === Many other industries take into account distribution coefficients, for example in the formulation of make-up, topical ointments, dyes, hair colors and many other consumer products.
Sources: en.wikipedia.org
Under normal conditions, osteocytes express high amounts of TGF-β and thus repress bone resorption, but when bone grows old, the expression levels of TGF-β decrease, and the expression of osteoclast-stimulatory factors, such as RANKL and M-CSF increases, bone resorption is then enhanced, leading to net bone loss. Mechanical stimulation of osteocytes results in opening of hemichannels to release PGE2 and ATP, among other biochemical signaling molecules, which play a crucial role in maintaining the balance between bone formation and resorption. Osteocyte cell death can occur in association with pathologic conditions such as osteoporosis and osteoarthritis, which leads to increased skeletal fragility, linked to the loss of ability to sense microdamage and/or signal repair. Oxygen deprivation that occurs as the result of immobilization (bed rest), glucocorticoid treatment, and withdrawal of oxygen have all been shown to promote osteocyte apoptosis. It is now recognized that osteocytes respond in a variety of ways to the presence of implant biomaterials.
Benzodiazepines have a unique history in that they were responsible for the largest-ever class-action lawsuit against drug manufacturers in the United Kingdom, involving 14,000 patients and 1,800 law firms that alleged the manufacturers knew of the dependence potential but intentionally withheld this information from doctors. At the same time, 117 general practitioners and 50 health authorities were sued by patients to recover damages for the harmful effects of dependence and withdrawal. This led some doctors to require a signed consent form from their patients and to recommend that all patients be adequately warned of the risks of dependence and withdrawal before starting treatment with benzodiazepines. The court case against the drug manufacturers never reached a verdict; legal aid had been withdrawn and there were allegations that the consultant psychiatrists, the expert witnesses, had a conflict of interest. The court case fell through, at a cost of £30 million, and led to more cautious funding through legal aid for future cases. This made future class action lawsuits less likely to succeed, due to the high cost from financing a smaller number of cases, and increasing charges for losing the case for each person involved. Although antidepressants with anxiolytic properties have been introduced, and there is increasing awareness of the adverse effects of benzodiazepines, prescriptions for short-term anxiety relief have not significantly dropped.
=== 2025 elections === On October 5, 2024, Duterte announced that he will run for mayor of Davao City, with his son, incumbent Mayor Sebastian Duterte, as his running mate for vice mayor in 2025. He also rejected calls for him to run for senator, citing his old age. Duterte officially filed his candidacy on October 7; however, on November 7, he welcomed the candidacy of his former cabinet secretary, former Civil Service Commission chairperson Karlo Nograles as Davao City mayor, adding he is retired and wishes to give the position to the next generation. In May 2025, Duterte was elected as mayor despite his detention at The Hague by the ICC. However, he was unable to take his oath on the start of his term on June 30, 2025, due to his imprisonment. As a result, his son Sebastian, who was elected vice mayor, became acting mayor. On January 23, 2026, Sebastian was sworn in as mayor of Davao City, following his father's failure to take the oath of office within the six-month prescribed period due to his detention.
Obesity in Brazil is a major public health challenge and one of the leading risk factors for non-communicable diseases in the country. Brazil is the largest country in South America and the fifth most populous in the world, with approximately 215 million inhabitants. Since the early 21st century, Brazil has experienced a substantial increase in obesity and overweight prevalence among adults, reflecting changes in dietary patterns, physical activity levels, urbanisation, and socioeconomic conditions. According to data from the Brazilian Ministry of Health's Vigilância de Fatores de Risco e Proteção para Doenças Crônicas por Inquérito Telefônico (transl. Surveillance of Risk and Protective Factors for Chronic Diseases via Telephone Survey) (Vigitel), obesity prevalence among adults living in the 26 Brazilian state capitals and the Federal District more than doubled between 2006 and 2024.
Sources: en.wikipedia.org
Following the invasion, it formed part of Task Force Black/Knight to combat the post invasion insurgency; in late 2005/early 2006, the SAS were integrated into JSOC and focused its counterinsurgency efforts on combating al-Qaeda in Iraq and the Sunni insurgency alongside Delta Force. The counter-insurgency was successful, and the UKSF mission in Iraq ended in May 2009. Overall, more than 3,500 terrorists were "taken off the streets" of Baghdad by 22 SAS. Various British newspapers have speculated on SAS involvement in Operation Ellamy and the 2011 Libyan civil war. The Daily Telegraph reports that "defence sources have confirmed that the SAS has been in Libya for several weeks, and played a key role in coordinating the fall of Tripoli." While The Guardian reports "They have been acting as forward air controllers – directing pilots to targets – and communicating with NATO operational commanders. They have also been advising rebels on tactics." Members of the Special Air Service were deployed to Northern Iraq in late August 2014, and according to former SIS chief Richard Barrett, would also be sent to Syria, tasked with trying to track down the Islamic State of Iraq and the Levant (ISIL) terrorist group that the press labelled the Beatles. Since the 1990s SAS officers have risen to senior appointments in the British Armed Forces. General Peter de la Billière was the commander in chief of the British forces in the 1990 Gulf War. General Michael Rose became commander of the United Nations Protection Force in Bosnia in 1994.
== Classes and roles == Bacterial glutathione transferases are widely distributed in aerobic bacteria and are classified into several classes. These classes are organized according to the protein sequence and structure. In bacteria, the theta class GSTs includes all of the currently known bacterial glutathione transferases. Between classes, these proteins have less than 25% sequence identity, while members of the same class match about 40% amino acid sequence identity. In comparison to eukaryotes, studies have shown that most of the residues that are highly conserved in theta and other bacterial class GSTs are not retained in those of the alpha, mu, and pi classes of eukaryotic GSTs. The considerable amount of protein sequence variation has led to the general belief that GSTs carry out a very wide variety of glutathione-dependent conjugation functions. No other currently known proteins have the same overall topology as GST enzymes. Bacterial glutathione transferases are not detected in anaerobic bacteria or archaea. These antioxidant enzymes are a part of the glutathione biosynthetic pathway, which is present in cyanobacteria, proteobacteria, and certain Gram-negative bacteria. Bacterial GSTs are involved in a variety of distinct processes such as biotransformation of toxic compounds, protection against several stresses, and antibacterial drug resistance. GSTs also have important roles in metabolism, such as signaling-ligand biosynthesis, tyrosine depredation, peroxide breakdown, and dehydroascorbate reduction.
=== Possible expansion into other Latin American nations === In August of 2026, while visiting Panama, Hegseth proclaimed that the United States has made a military agreement with Colombia, Guatemala and Honduras to combat criminal drug organizations. Hegseth added that like the attacks on boats that the U.S. had been conducting in the East Pacific and the Caribbean, the attacks on drug traffickers on land would be the same. In addition, Hegseth stated that the U.S. would continue to pursue military cooperation with Ecuador. However, Guatemala later publicly repudiated Hegseth's claims.
== Chemistry == Teicoplanin (TARGOCID, marketed by Sanofi Aventis Ltd) is actually a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, termed teicoplanin A3-1 — a fused ring structure to which two carbohydrates (mannose and N-acetylglucosamine) are attached. The major and minor components also contain a third carbohydrate moiety — β-D-glucosamine — and differ only by the length and conformation of a side-chain attached to it. Teicoplanin A2-4 and RS-3 have chiral side chains while all other side chains are achiral. Teicoplanin A3 lacks both the side chains as well as the β-D-glucosamine moiety. The structures of the teicoplanin core and the side-chains that characterize the five major as well as four minor teicoplanin compounds are shown below.
It is generally considered less sedating and causes less tolerance than traditional 1,4-benzodiazepines, partially because it binds less to subunits that cause sedation. N-desmethylclobazam, is the active metabolite of the benzodiazepine, clobazam. It works by enhancing GABA-activated chloride influx at GABAA receptor, creating a hyperpolarizing, inhibitory postsynaptic potential. The primary active metabolite N-desmethylclobazam, circulates at higher levels than the parent drug at therapeutic dosages. Plasma concentrations of N-desmethylclobazam are approximately 3–5 times higher than those of clobazam. The primary active metabolite of clobazam, is crucial for its prolonged anti-anxiety and anti-epileptic effects, acting similarly on GABAA receptors but with potentially greater importance in long-term therapy, especially for epilepsy, and is largely responsible for the drug's overall clinical action. It was also reported that these effects were inhibited by the GABA antagonist flumazenil, and that clobazam acts more efficiently in GABA-deficient brain tissue.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.